...
首页> 外文期刊>Clinical & developmental immunology. >Hair Follicle Dermal Sheath Derived Cells Improve Islet Allograft Survival without Systemic Immunosuppression
【24h】

Hair Follicle Dermal Sheath Derived Cells Improve Islet Allograft Survival without Systemic Immunosuppression

机译:毛囊真皮鞘衍生细胞可改善胰岛同种异体移植的存活,而无需全身性免疫抑制

获取原文
获取原文并翻译 | 示例

摘要

Immunosuppressive drugs successfully prevent rejection of islet allografts in the treatment of type I diabetes. However, the drugs also suppress systemic immunity increasing the risk of opportunistic infection and cancer development in allograft recipients. In this study, we investigated a new treatment for autoimmune diabetes using naturally immune privileged, hair follicle derived, autologous cells to provide localized immune protection of islet allotransplants. Islets from Balb/c mouse donors were cotransplanted with syngeneic hair follicle dermal sheath cup cells (DSCC, group 1) or fibroblasts (FB, group 2) under the kidney capsule of immune-competent, streptozotocin induced, diabetic C57BL/6 recipients. Group 1 allografts survived significantly longer than group 2 (32.2 ± 12.2 versus 14.1 ± 3.3 days, P < 0.001) without administration of any systemic immunosuppressive agents. DSCC reduced T cell activation in the renal lymph node, prevented graft infiltrates, modulated inflammatory chemokine and cytokine profiles, and preserved better beta cell function in the islet allografts, but no systemic immunosuppression was observed. In summary, DSCC prolong islet allograft survival without systemic immunosuppression by local modulation of alloimmune responses, enhancing of beta cell survival, and promoting of graft revascularization. This novel finding demonstrates the capacity of easily accessible hair follicle cells to be used as local immunosuppression agents in islet transplantation.
机译:免疫抑制药物在治疗I型糖尿病中成功地阻止了胰岛同种异体移植的排斥反应。但是,该药物还抑制全身免疫,从而增加了同种异体移植接受者机会性感染和癌症发展的风险。在这项研究中,我们研究了一种利用天然免疫特权,毛囊衍生的自体细胞对自身免疫性糖尿病进行治疗的新方法,以提供胰岛同种异体移植的局部免疫保护。将来自Balb / c小鼠供体的胰岛与同基因毛囊真皮鞘杯细胞(DSCC,第1组)或成纤维细胞(FB,第2组)在具有免疫能力的链脲佐菌素诱导的糖尿病C57BL / 6受体的肾囊下共移植。第1组同种异体移植物的存活时间明显长于第2组(32.2±12.2对14.1±3.3天,P <0.001),而未施用任何全身性免疫抑制剂。 DSCC减少了肾淋巴结中的T细胞活化,防止了移植物浸润,调节了炎症趋化因子和细胞因子的分布,并在胰岛同种异体移植物中保留了更好的β细胞功能,但未观察到全身免疫抑制。总之,DSCC可通过局部调节同种免疫反应,增强β细胞存活和促进移植血管重建来延长胰岛同种异体移植的存活,而无需全身免疫抑制。这一新发现证明了易于获取的毛囊细胞在胰岛移植中用作局部免疫抑制剂的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号